David Hyman, MD
Larotrectinib (LOXO-101), an oral inhibitor of tropomyosin receptor kinases (TRKs), is being developed in a novel multifaceted clinical trial program that spans cancer types and age groupings and is helping to set the pace for an emerging tumor-agnostic drug development paradigm.
Table. Clinical Trials in the Larotrectinib Development Program. (Click to enlarge image)
Hyman is the primary investigator for the NAVIGATE trial and is the head of the larotrectinib trial program.
Rationale for Targeting TRK
, and NTRK3
genes encode the TRKA, TRK B, and TRK C proteins, respectively. These receptors play a key role in the development of the central and peripheral nervous systems. According to Hyman, these proteins have a limited role in normal tissue biology after embryologic development in the function of the central nervous system: TRK A is primarily associated with the development of pain sensation and thermoregulation; TRK B is involved in movement, memory, mood, and weight homeostasis; and TRK C is associated with proprioception.1
... to read the full story